TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice

Journal of Hepatology

Volumn 62, Issue 2, 2015, Pages 371-379

  Jiang, Shiming ^a,b   Minter, Lindsey Cauthen ^a,b,c   Stratton, Sabrina A ^a,b   Yang, Peirong ^b   Abbas, Hussein A ^b,c   Akdemir, Zeynep Coban ^a,b,c   Pant, Vinod ^b   Post, Sean ^b   Gagea, Mihai ^b   Lee, Richard G ^d   Lozano, Guillermina ^b,c   Barton, Michelle Craig ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d ISIS PHARMACEUTICALS   (United States)

Author keywords

HCC; Hepatic lesions; Histone reader; NAFLD; NASH; Steatosis

Indexed keywords

ALBUMIN; FATTY ACID; PROTEIN; PROTEIN TRIM24; RNA; STEROID; UNCLASSIFIED DRUG; LIPID; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CHROMATIN IMMUNOPRECIPITATION; ENDOPLASMIC RETICULUM STRESS; EXON; EXPERIMENTAL MODEL; FIBROSIS; GENE; GENE EXPRESSION; HOMEOSTASIS; IN VIVO STUDY; INTRAABDOMINAL FAT; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIVER CELL CARCINOMA; LIVER INJURY; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SPONTANEOUS HEPATIC LIPID ACCUMULATION; STEATOSIS; UNFOLDED PROTEIN RESPONSE; ZONA PELLUCIDA; ANIMAL; BIOSYNTHESIS; DISEASE COURSE; EXPERIMENTAL LIVER NEOPLASM; FATTY LIVER; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; LIVER; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FATTY LIVER; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPIDS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSCRIPTION FACTORS;

EID: 84922249589     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.09.026     Document Type: Article

References (41)

1. Takahashi Y, Soejima Y, Fukusato T. Animal models of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. World J Gastroenterol 2012; 18: 2300-2308.
2. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: Old questions and new insights. Science 2011; 332: 1519-1523.
3. Peng H, Feldman I, Rauscher 3rd FJ. Hetero-oligomerization among the TIF family of RBCC/TRIM domain-containing nuclear cofactors: A potential mechanism for regulating the switch between coactivation and corepression. J Mol Biol 2002; 320: 629-644.
4. Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, Qin J, et al. Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A 2009; 106: 11612-11616.
5. Chambon M, Orsetti B, Berthe ML, Bascoul-Mollevi C, Rodriguez C, Duong V, et al. Prognostic significance of TRIM24/TIF-1alpha gene expression in breast cancer. Am J Pathol 2011; 178: 1461-1469.
6. Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature 2010; 468: 927-932.
7. Tisserand J, Khetchoumian K, Thibault C, Dembele D, Chambon P, Losson R. Tripartite motif 24 (Trim24/Tif1alpha) tumour suppressor protein is a novel negative regulator of interferon (IFN)/signal transducers and activators of transcription (STAT) signaling pathway acting through retinoic acid receptor alpha (Raralpha) inhibition. J Biol Chem 2011; 286: 33369-33379.
8. Cui Z, Cao W, Li J, Song X, Mao L, Chen W. TRIM24 overexpression is common in locally advanced head and neck squamous cell carcinoma and correlates with aggressive malignant phenotypes. PLoS One 2013; 8: E63887.
9. Li H, Sun L, Tang Z, Fu L, Xu Y, Li Z, et al. Overexpression of TRIM24 correlates with tumour progression in non-small cell lung cancer. PLoS One 2012; 7: E37657.
10. Zhang LH, Yin AA, Cheng JX, Huang HY, Li XM, Zhang YQ, et al. TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway. Oncogene 2014; 33: 1-11.
11. Liu X, Huang Y, Yang D, Li X, Liang J, Lin L, et al. Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma. PLoS One 2014; 9: E85462.
12. Khetchoumian K, Teletin M, Tisserand J, Mark M, Herquel B, Ignat M, et al. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet 2007; 39: 1500-1506.
13. Herquel B, Ouararhni K, Martianov I, Le Gras S, Ye T, Keime C, et al. Trim24- repressed VL30 retrotransposons regulate gene expression by producing noncoding RNA. Nat Struct Mol Biol 2013; 3: 339-346.
14. Matsui T, Leung D, Miyashita H, Maksakova IA, Miyachi H, Kimura H, et al. Proviral silencing in embryonic stem cells requires the histone methyltransferase ESET. Nature 2010; 464: 927-931.
15. Mark M, Teletin M, Antal C, Wendling O, Auwerx J, Heikkinen S, et al. Histopathology in mouse metabolic investigations. Curr Protoc Mol Biol 2007; Chapter 29, Unit 29B 24.
16. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005; 46: 872-884.
17. Carr TP, Andresen CJ, Rudel LL. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 1993; 26: 39-42.
18. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer 2011; 11: 792-804.
19. Herquel B, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, Mark M, et al. Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci U S A 2011; 108: 8212-8217.
20. Fon Tacer K, Rozman D. Non-alcoholic fatty liver disease: Focus on lipoprotein and lipid deregulation. J Lipids 2011; 2011: 783976.
21. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010; 28: 511-515.
22. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-1080.
23. Ruthenburg AJ, Li H, Patel DJ, Allis CD. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 2007; 8: 983-994.
24. Katzenellenbogen BS. Estrogen receptors: Bioactivities and interactions with cell signaling pathways. Biol Reprod 1996; 54: 287-293.
25. Cheskis BJ, Greger JG, Nagpal S, Freedman LP. Signaling by estrogens. J Cell Physiol 2007; 213: 610-617.
26. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
27. Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014; 25: 473-486.
28. Chavez AO, Kamath S, Jani R, Sharma LK, Monroy A, Abdul-Ghani MA, et al. Effect of short-term free Fatty acids elevation on mitochondrial function in skeletal muscle of healthy individuals. J Clin Endocrinol Metab 2010; 95: 422-429.
29. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, et al. Chromosomewide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005; 122: 33-43.
30. Kato S, Sasaki H, Suzawa M, Masushige S, Tora L, Chambon P, et al. Widely spaced, directly repeated PuGGTCA elements act as promiscuous enhancers for different classes of nuclear receptors. Mol Cell Biol 1995; 15: 5858-5867.
31. Amengual J, Ribot J, Bonet ML, Palou A. Retinoic acid treatment increases lipid oxidation capacity in skeletal muscle of mice. Obesity 2008; 16: 585-591.
32. Hoekstra M, Li Z, Kruijt JK, Van Eck M, Van Berkel TJ, Kuiper J. The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. J Hepatol 2010; 52: 244-251.
33. Starley BQ, Calcagno CJ, Harrison SA. Non-alcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010; 51: 1820-1832.
34. Hebbard L, George J. Animal models of non-alcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011; 8: 35-44.
35. Zhang XQ, Xu CF, Yu CH, Chen WX, Li YM. Role of endoplasmic reticulum stress in the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1768-1776.
36. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, et al. Hepatocytespecific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004; 113: 1774-1783.
37. Miki T, Fleming TP, Crescenzi M, Molloy CJ, Blam SB, Reynolds SH, et al. Development of a highly efficient expression cDNA cloning system: Application to oncogene isolation. Proc Natl Acad Sci U S A 1991; 88: 5167-5171.
38. Le Douarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat P, et al. The Nterminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J 1995; 14: 2020-2033.
39. Breuhahn K, Vreden S, Haddad R, Beckebaum S, Stippel D, Flemming P, et al. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 2004; 64: 6058-6064.
40. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) 2009; 87: 679-695.
41. Kim NH, Kim JH, Kim YJ, Yoo HJ, Kim HY, Seo JA, et al. Clinical and metabolic factors associated with development and regression of non-alcoholic fatty liver disease in nonobese subjects. Liver Int 2014; 34: 604-611.